GWPH - GW Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.64
+0.61 (+0.45%)
At close: 4:00PM EDT

138.00 +0.36 (0.26%)
After hours: 5:00PM EDT

Stock chart is not supported by your current browser
Previous Close137.03
Open137.20
Bid137.59 x 1200
Ask137.73 x 900
Day's Range136.00 - 138.39
52 Week Range90.14 - 196.00
Volume390,468
Avg. Volume429,429
Market Cap4.188B
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateOct 1, 2019 - Oct 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est227.31
Trade prices are not sourced from all markets
  • Abbott Partners With Sanofi to Upgrade Diabetes Management
    Zacks

    Abbott Partners With Sanofi to Upgrade Diabetes Management

    Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

  • The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry
    Zacks

    The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry

    The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry

  • Why Investors Should Buy GW Pharmaceuticals Stock
    InvestorPlace

    Why Investors Should Buy GW Pharmaceuticals Stock

    Some call GW Pharmaceuticals (NASDAQ:GWPH) a cannabis company. Others, like GW Pharma CEO Justin Gover, believe it is a biotech company. Regardless of the industry in which the company operates, the important thing is that investors understand GW stock is an excellent long-term investment. Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere's why. A Long Runway of GrowthCurrently, GW has one cannabis-derived drug, Epidiolex, that's available in the U.S. Another, Sativex, is in development, and there are several others in the pipeline that should make their way into the marketplace over the next several years. In the second quarter, Epidiolex generated net sales of $68.4 million, 204% higher than the drug's sales in the first quarter. Overall, GW's Q2 revenues were $72.0 million, 2,080% higher than a year earlier. * 7 Tech Stocks You Should Avoid Now GW began selling its cannabis-derived products in the U.S. in November 2018, and sales of its drugs in the largest European nations, France, Germany, and the U.K., are expected to begin later in 2019. Investment bank Evercore ISI predicts that U.S. peak sales of Epidiolex could be as high as $1.3 billion. Derived from a substance in cannabis called cannabidiol (CBD), Epidiolex is used to treat Dravet syndrome and Lennox-Gastaut syndrome, both of which are forms of childhood epilepsy. The fact that Epidiolex is the first FDA-approved medicine derived from cannabis has convinced many that GW is a marijuana stock. GW Isn't ProfitableLike many early-stage biotech companies, GW's expenses are high and its revenues are low. But the fact that it's generating meaningful revenue is certainly positive for GW stock. In the first six months of 2019, GW had an operating loss of $80.7 million, 46% lower than in the same period a year earlier. Once Epidiolex becomes available in Europe, GW's operating loss should drop much further. "In Europe, we are pleased to have recently received the positive opinion from (regulators) which clears the way for an expected approval in October," GW's CEO, Gover, was quoted as saying in an Aug. 6 press release. "Our European commercial organization is in place and will be ready to launch in the first European markets upon approval," he added. JPMorgan analyst Cory Kasimov raised his price target on GW stock by $18 in late August to $232. versus the $141 price at which GW stock closed on Friday. "A continued strong U.S. launch (of Epidiolex) and EU approval in October." along with the likely use of the drug to start treating Tuberous Sclerosis Complex in 2020, should enable GW stock to climb further, Kasimov stated in a note to clients. Tuberous Sclerosis Complex is a genetic disorder that results in noncancerous tumors spreading throughout the body. One of the side effects of the complex is epilepsy, which Epidiolex is intended to treat. The company estimates that as many as 80,000 Americans and as many as 2 million people worldwide are affected by TSC. The Bottom Line on GW StockAnother InvestorPlace columnist, Josh Enomoto, wrote something about GW stock in April that highlights the company's potential."In many ways, GWPH stock is the Amazon (NASDAQ:AMZN) of healthcare: their core ingredient, cannabis, is dirt cheap. Therefore, the underlying company has the ability to disrupt the drug-making industry like no one's business," Josh stated in an article published on April 30. As I see it, GW Pharmaceuticals is the best cannabis stock that isn't actually a cannabis stock. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post Why Investors Should Buy GW Pharmaceuticals Stock appeared first on InvestorPlace.

  • Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
    Zacks

    Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

    With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

  • Medtronic (MDT) Earns Dow Jones Sustainability Recognition
    Zacks

    Medtronic (MDT) Earns Dow Jones Sustainability Recognition

    Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.

  • Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
    Zacks

    Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes

    Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.

  • CryoLife Enters Agreement With Endospan for Aortic Stent
    Zacks

    CryoLife Enters Agreement With Endospan for Aortic Stent

    CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

  • ECB Launches Fresh Stimulus! Grab 5 European Stocks Now
    Zacks

    ECB Launches Fresh Stimulus! Grab 5 European Stocks Now

    The ECB has unveiled a sweeping stimulus package in an attempt to prevent a sluggish Eurozone economy from grinding to a halt.

  • Benzinga

    Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal

    Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential. Israel-based Teva Pharmaceutical Industries ...

  • Medical Cannabis: A Hot Topic at Events Across the World
    Market Realist

    Medical Cannabis: A Hot Topic at Events Across the World

    These days, experts are discussing the pros and cons of medical cannabis at multiple conferences and summits around the world.

  • Benzinga

    14 Top Cannabis Stocks Targeted By Short Sellers

    After a weak couple of months, cannabis stocks rallied in the first week of September . That rally seems to have stalled so far in the second week of the month. S3 Partners analyst Ihor Dusaniwsy said ...

  • Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
    Zacks

    Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring

    Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.

  • Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
    Zacks

    Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care

    Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.

  • Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?
    Zacks

    Buy Aurora Cannabis (ACB) Stock Before Earnings, Despite Marijuana Volatility?

    Despite growing sales and wider legalization, many pot stocks have been insanely volatile as Wall Street and investors try to wrap their heads around the marijuana industry. So should you think about buying "cheap" Aurora Cannabis (ACB) Stock before Q4 earnings?

  • LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
    Zacks

    LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

    LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

  • Here's Why You Should Invest in Chemed (CHE) Stock Right Now
    Zacks

    Here's Why You Should Invest in Chemed (CHE) Stock Right Now

    Investors continue to be optimistic about Chemed's (CHE) performance.

  • Here's Why You Should Invest in Edwards Lifesciences (EW) Now
    Zacks

    Here's Why You Should Invest in Edwards Lifesciences (EW) Now

    Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.

  • Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year?
    Zacks

    Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire

    GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

    GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019 at 9:55 a.m. ET in New York, NY.

  • Benzinga

    Cannabis Countdown: Top 10 Marijuana Industry News Stories Of The Week

    Americans are twice as likely to say that alcohol is “very harmful” than say the same about marijuana, according to a recent survey. The Ontario Cannabis Store sells licensed producers data based on customers’ addresses, Global News has learned.

  • Is the U.S. Getting on Board With Cannabis Legalization?
    Motley Fool

    Is the U.S. Getting on Board With Cannabis Legalization?

    Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.

  • 5 of the Most Cash-Rich Cannabis Stocks
    Motley Fool

    5 of the Most Cash-Rich Cannabis Stocks

    You could rightly say that these five pot stocks are swimming with green.

  • LabCorp's Covance Launches Laboratory Data Management Service
    Zacks

    LabCorp's Covance Launches Laboratory Data Management Service

    LabCorp (LH) expands service portfolio through Covance's data management portal.

  • Benzinga

    UK NHS Says Epidiolex Too Expensive, GW Pharma Says Company 'Remains Hopeful'

    GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH )'s CBD drug Epidiolex, which treats epilepsy, has been deemed too expensive by the U.K.’s National Health Service, according to an  iNEWS report. Epidiolex has ...

  • 5 Ways to Invest in the Marijuana Craze With Ancillary Stocks
    Motley Fool

    5 Ways to Invest in the Marijuana Craze With Ancillary Stocks

    You don't have to buy cannabis growers or pot retailers to make money in the marijuana space.